Updates from a single-center phase 2 study of PD-1 inhibitor combined with hypomethylating agent plus CAG regimen in patients with relapsed/refractory acute myeloid leukemia

Updates from a single-center phase 2 study of PD-1 inhibitor combined with hypomethylating agent plus CAG regimen in patients with relapsed/refractory acute myeloid leukemia

IntroductionAnti-PD-1 monotherapy has shown limited clinical efficacy in patients with relapsed/refractory acute myeloid leukemia (r/r AML). Our study aimed to analyze the effectiveness and safety of combining tislelizumab with a hypomethylating agent (HMA) plus CAG regimen in treating patients with...

Full description

Saved in:
Bibliographic Details
Main Authors: Hui-Sheng Zhou, Yong-Feng Su, Jun Wang, Ya-Lei Hu, An Wang, Lei Xu, Yi-Zhi Wang, Xuan Zheng, Yu-Qing Li, Kai-Li Min, Chun-Ji Gao, Dai-Hong Liu, Xiao-Ning Gao
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-04-01
Series:Frontiers in Immunology
Subjects:
acute myeloid leukemia
DNA hypomethylation agent
PD-1 inhibitor
relapse
refractory
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2025.1533467/full
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items